Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 4/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | CDK7 | P50613 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | CDC7 | O00311 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 14/20 | 0.38 |
| ▸ | CSF1R | P07333 | 9/20 | 0.38 |
| ▸ | FLT1 | P17948 | 9/20 | 0.38 |
| ▸ | KIT | P10721 | 9/20 | 0.38 |
| ▸ | FLT3 | P36888 | 9/20 | 0.38 |
| ▸ | LCK | P06239 | 8/20 | 0.38 |
| ▸ | LYN | P07948 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680979 | 0.81 | MAP4K4 (0.44) | PRKACACLK4MAP4K4GSK3BCDK7 | |
| SCHEMBL11614115 | 0.81 | CDC7 (0.41) | PRKACACLK4MAP4K4GSK3BCDK7 | |
| SCHEMBL16681050 | 0.78 | PDPK1 (0.42) | PRKACACLK4MAP4K4GSK3BCDK7 | |
| SCHEMBL1317469 | 0.78 | PDPK1 (0.50) | PRKACACLK4MAP4K4GSK3BCDK7 | |
| SCHEMBL16681057 | 0.78 | GAA (0.58) | PRKACACLK4MAP4K4GSK3BCDK7 | |
| SCHEMBL85022 | 0.77 | MAP4K4 (0.40) | PRKACACLK4MAP4K4GSK3BCDK7 | |
| SCHEMBL84391 | 0.77 | EIF4A3 (0.39) | PRKACACLK4MAP4K4GSK3BCDK7 | |
| SCHEMBL91427 | 0.77 | CLK4 (0.37) | PRKACACLK4MAP4K4GSK3BCDK7 | |
| SCHEMBL29324815 | 0.75 | SGK1 (0.31) | SGK1 | |
| SCHEMBL15818542 | 0.74 | KDR (0.41) | PRKACACLK4MAP4K4GSK3BCDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | PRKACA 51/4885CLK4 974/4885MAP4K4 117/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | PRKACA 8/4885CLK4 1046/4885MAP4K4 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.